Obesity pharmaceutical correction in metabolic syndrome patients
Very high prevalence of obesity and metabolic syndrome (MS) is well known. The need for early treatment start and more selective pharmaceutical treatment of MS has been noted in many publications. As pathogenetic therapy, numerous methods for body mass (BM) reduction have been proposed, due to well-...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | Russian |
Published: |
«SILICEA-POLIGRAF» LLC
2005-08-01
|
Series: | Кардиоваскулярная терапия и профилактика |
Subjects: | |
Online Access: | https://cardiovascular.elpub.ru/jour/article/view/991 |
id |
doaj-be1b2df7405c426b993f444a3b297916 |
---|---|
record_format |
Article |
spelling |
doaj-be1b2df7405c426b993f444a3b2979162021-07-28T13:50:41Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01252005-08-01447984705Obesity pharmaceutical correction in metabolic syndrome patientsV. B. Mychka0I. E. Chazova1V. V. Gornostaev2V. B. Sergienko3A.L. Myasnikov Research Institute of Clinical Cardiology, Russian Cardiology Scientific and Clinical Complex, Ministry of Health of the Russian Federation, MoscowA.L. Myasnikov Research Institute of Clinical Cardiology, Russian Cardiology Scientific and Clinical Complex, Ministry of Health of the Russian Federation, MoscowA.L. Myasnikov Research Institute of Clinical Cardiology, Russian Cardiology Scientific and Clinical Complex, Ministry of Health of the Russian Federation, MoscowA.L. Myasnikov Research Institute of Clinical Cardiology, Russian Cardiology Scientific and Clinical Complex, Ministry of Health of the Russian Federation, MoscowVery high prevalence of obesity and metabolic syndrome (MS) is well known. The need for early treatment start and more selective pharmaceutical treatment of MS has been noted in many publications. As pathogenetic therapy, numerous methods for body mass (BM) reduction have been proposed, due to well-known prevalent role of obesity in MS pathogenesis. Because of various reasons, many medications haven’t achieved wide acceptance in clinical settings. The article summarizes the experience in BM reduction with an effective drug – orlistat (Xenical®). Based on the authentic authors’ data, beneficial effects of orlistat on carbohydrate and lipid metabolism, 24-hour blood pressure profile, and cerebral perfusion are demonstrated. The authors prove that orlistat is highly recommended for cardiovascular complication risk reduction in MS patients.https://cardiovascular.elpub.ru/jour/article/view/991metabolic syndromearterial hypertensionobesityorlistat |
collection |
DOAJ |
language |
Russian |
format |
Article |
sources |
DOAJ |
author |
V. B. Mychka I. E. Chazova V. V. Gornostaev V. B. Sergienko |
spellingShingle |
V. B. Mychka I. E. Chazova V. V. Gornostaev V. B. Sergienko Obesity pharmaceutical correction in metabolic syndrome patients Кардиоваскулярная терапия и профилактика metabolic syndrome arterial hypertension obesity orlistat |
author_facet |
V. B. Mychka I. E. Chazova V. V. Gornostaev V. B. Sergienko |
author_sort |
V. B. Mychka |
title |
Obesity pharmaceutical correction in metabolic syndrome patients |
title_short |
Obesity pharmaceutical correction in metabolic syndrome patients |
title_full |
Obesity pharmaceutical correction in metabolic syndrome patients |
title_fullStr |
Obesity pharmaceutical correction in metabolic syndrome patients |
title_full_unstemmed |
Obesity pharmaceutical correction in metabolic syndrome patients |
title_sort |
obesity pharmaceutical correction in metabolic syndrome patients |
publisher |
«SILICEA-POLIGRAF» LLC |
series |
Кардиоваскулярная терапия и профилактика |
issn |
1728-8800 2619-0125 |
publishDate |
2005-08-01 |
description |
Very high prevalence of obesity and metabolic syndrome (MS) is well known. The need for early treatment start and more selective pharmaceutical treatment of MS has been noted in many publications. As pathogenetic therapy, numerous methods for body mass (BM) reduction have been proposed, due to well-known prevalent role of obesity in MS pathogenesis. Because of various reasons, many medications haven’t achieved wide acceptance in clinical settings. The article summarizes the experience in BM reduction with an effective drug – orlistat (Xenical®). Based on the authentic authors’ data, beneficial effects of orlistat on carbohydrate and lipid metabolism, 24-hour blood pressure profile, and cerebral perfusion are demonstrated. The authors prove that orlistat is highly recommended for cardiovascular complication risk reduction in MS patients. |
topic |
metabolic syndrome arterial hypertension obesity orlistat |
url |
https://cardiovascular.elpub.ru/jour/article/view/991 |
work_keys_str_mv |
AT vbmychka obesitypharmaceuticalcorrectioninmetabolicsyndromepatients AT iechazova obesitypharmaceuticalcorrectioninmetabolicsyndromepatients AT vvgornostaev obesitypharmaceuticalcorrectioninmetabolicsyndromepatients AT vbsergienko obesitypharmaceuticalcorrectioninmetabolicsyndromepatients |
_version_ |
1721271497689923584 |